Aptevo Therapeutics Inc.
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.05% | 1.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.23% | -3.92% | |||
| Operating Income | -22.23% | 3.92% | |||
| Income Before Tax | -21.68% | 3.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.68% | 3.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.68% | 3.18% | |||
| EBIT | -22.23% | 3.92% | |||
| EBITDA | -22.41% | 3.77% | |||
| EPS Basic | 73.47% | 90.44% | |||
| Normalized Basic EPS | 77.82% | 90.44% | |||
| EPS Diluted | 73.47% | 90.44% | |||
| Normalized Diluted EPS | 77.82% | 90.44% | |||
| Average Basic Shares Outstanding | 448.57% | 912.48% | |||
| Average Diluted Shares Outstanding | 448.57% | 912.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||